Pamrevlumab, a humanized anti-CTGF antibody, has been tested in clinical trials for muscular dystrophy, pancreatic cancer, liver fibrosis, idiopathic pulmonary fibrosis, and type 1 and 2 diabetes (Ramazani et al., 2018). This evidence concerns the gene CCN2 and idiopathic pulmonary fibrosis.